Evaluation of the clinical performance of the Beckman Coulter Access® AbHBsII immunoassay for the detection of hepatitis B surface antibodies

Journal of Clinical Virology

Volumn 37, Issue 3, 2006, Pages 213-217

  Motte, Anne ^a   Colson, Philippe ^a   Tamalet, Catherine ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Anti HBs antibodies; Commercially enzymo immunological assays; Hepatitis B virus; Sensitivity; Specificity

Indexed keywords

HEPATITIS B SURFACE ANTIBODY;

ACUTE LEUKEMIA; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVALUATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; INFLAMMATION; INTERMETHOD COMPARISON; LABORATORY TEST; MALE; MEDICAL RECORD REVIEW; PREDICTION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; SERUM; VACCINATION;

CHEMILUMINESCENT MEASUREMENTS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOASSAY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33749604858     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.08.004     Document Type: Article

References (14)

1. Commission decision on common technical specifications for in vitro-diagnostic medical devices. Official J Eur Commun 2002;L131:17-30.
2. Di Paola D., Tisone G., Piccolo P., Lenci I., Zazza S., and Angelico M. Low dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Tranplantation 77 8 (2004) 1203-1208
3. Egwim C., and Botero R.C. Is hepatitis B Immunoglobulin prophylaxis needed for liver transplantation in the era of new antivirals?. Tranplant Proc 37 (2005) 2200-2204
4. Floreani A., Baldo V., Cristofoletti M., Renzulli G., Valeri A., Zanetti C., et al. Long-term persistance of anti-HBs after vaccination against HB V: an 18 year experience in health care workers. Vaccine 22 (2004) 607-610
5. Greub G., and Frei P.C. Presence of low levels of anti-HBs antibody in so-called "anti-HBc alone" subjects. Liver 21 6 (2001) 380-383
6. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommandations of the Immunization Practices Advisory Committee (ACIP). Morb Mortal Weekly Rep 1991;40(RR-13):1-19.
7. Heijtink R.A., Schneeberger P.M., Postma B., and Crombach W. Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/L seroprotection levels unreliable. Vaccine 20 (2002) 2899-2905
8. Kane M. Global programme for control of hepatitis B infection. Vaccine 13 Suppl 1 (1995) S47-S49
9. Kao J.H., and Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2 (2002) 395-403
10. Poland G.A., and Jacobson R.M. Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 351 (2004) 2832-2838
11. Sadler W.A., and Smith M.H. Estimation of imprecision in immunoassay quality assessment programmes. Ann Clin Biochem 24 Pt l (1987 Jan) 98-106
12. Sjogren M.H. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med 118 (2005) 34S-39S
13. Terrault N.A., and Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 7 3 (2003) 537-550
14. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 11 (1996) 1019-1027